Table 3.
Clinicopathologic correlation of HER-2.
| Sl no. | Attribute | HER-2 positive (n = 19) | HER-2 negative (n = 245) | p valuea overall | p valuea PTC | p valuea FTC | p valuea PDTC |
|---|---|---|---|---|---|---|---|
| 1. | Age in years (mean ± SD) | 46.5 ± 15.9 | 46.3 ± 15.5 | 0.945 | 0.131 | 0.173 | — |
| 2. | Gender (M : F) | 9 : 10 | 81 : 164 | 0.217 | 0.285 | 0.562 | — |
| 3. | Presence of PDAb, n (%) | 3 (15.8) | 87 (41.6) | 0.762 | 0.514 | 0.261 | — |
| 4. | Tumor size in cm (mean ± SD) | 4.9 ± 3.1 | 4.7 ± 2.8 | 0.027∗ | 1.000 | 0.014∗ | — |
| 5. | Multicentricity, n (%) | 6 (31.6) | 64 (26.8) | 0.603 | 1.000 | 1.000 | — |
| 6. | Extrathyroidal extension, n (%) | 7 (36.8) | 58 (24.1) | 0.269 | 0.358 | 0.266 | — |
| 7. | Lymph node metastases, n (%) | 9 (47.4) | 93 (38.1) | 0.468 | 0.411 | 0.290 | — |
| 8. | Metastases, n (%) | 3 (16.7) | 80 (32.8) | 0.195 | 0.186 | 0.219 | — |
| 9. | Recurrence, n (%) | 2 (10.5) | 23 (9.4) | 1 : 000 | 1.000 | 1.000 | — |
| 10. | Mean survival in months (n ± SE) | 151 ± 14.9 | 192 ± 7 | 0.792 | 0.090 | 0.391 | — |
aAll p values obtained on univariate analysis. b PDA, poorly differentiated areas. ∗Significant positive correlation of HER-2 expression and overall tumor size; ∗∗FTC tumor size.